Universe Pharmaceuticals INCUPCEarnings & Financial Report
Amylin Pharmaceuticals, Inc. was a biopharmaceutical company founded in 1987 that was based in San Diego, California. The company was engaged in the discovery, development, and commercialization of drug candidates for the treatment of diabetes, obesity, and other diseases. Amylin produced three drugs: Symlin, Byetta (exenatide) and Bydureon.
UPC Q2 2024 Key Financial Metrics
Revenue
$12.9M
Gross Profit
$3.4M
Operating Profit
$-1.7M
Net Profit
$-13.1M
Gross Margin
26.2%
Operating Margin
-13.5%
Net Margin
-101.7%
YoY Growth
N/A
Financial Flow
Universe Pharmaceuticals INC Q2 2024 Financial Summary
Universe Pharmaceuticals INC reported revenue of $12.9M for Q2 2024, with a net profit of $-13.1M (-101.7% margin). Cost of goods sold was $9.5M, operating expenses totaled $5.1M.
Key Financial Metrics
| Total Revenue | $12.9M |
|---|---|
| Net Profit | $-13.1M |
| Gross Margin | 26.2% |
| Operating Margin | -13.5% |
| Report Period | Q2 2024 |
Income Statement
| Q2 2022 | Q2 2023 | Q2 2024 | |
|---|---|---|---|
| Revenue | $24.2M | $18.5M | $12.9M |
| YoY Growth | N/A | N/A | N/A |
Balance Sheet
| Q2 2022 | Q2 2023 | Q2 2024 | |
|---|---|---|---|
| Assets | $71.4M | $70.4M | $49.4M |
| Liabilities | N/A | N/A | $22.7M |
| Equity | $61.2M | $47.1M | $26.7M |
Cash Flow
| Q2 2022 | Q2 2023 | |
|---|---|---|
| Operating CF | $6.1M | $4.8M |
More Companies
AZN
ASTRAZENECA PLC
Revenue
$14.5B
Net Profit
$2.4B
NVS
NOVARTIS AG
NVO
NOVO NORDISK A S
SNY
Sanofi
GSK
GSK plc
TAK
TAKEDA PHARMACEUTICAL CO LTD
ARGX
ARGENX SE
ALNY
ALNYLAM PHARMACEUTICALS, INC.
Revenue
$1.1B
Net Profit
$186.4M
ALC
ALCON INC
Revenue
$2.6B
Net Profit
$176.0M
TEVA
TEVA PHARMACEUTICAL INDUSTRIES LTD
Revenue
$4.7B
Net Profit
$481.0M